Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Common Equity (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Common Equity for 14 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 146.23% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.0 million through Dec 2025, up 146.23% year-over-year, with the annual reading at $61.0 million for FY2025, 146.23% up from the prior year.
  • Common Equity hit $61.0 million in Q4 2025 for Coherus Oncology, down from $87.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $156.2 million in Q2 2021 to a low of -$196.5 million in Q1 2023.
  • Historically, Common Equity has averaged -$36.6 million across 5 years, with a median of -$83.0 million in 2024.
  • Biggest five-year swings in Common Equity: crashed 1664.17% in 2023 and later skyrocketed 242.47% in 2025.
  • Year by year, Common Equity stood at $97.7 million in 2021, then plummeted by 240.62% to -$137.4 million in 2022, then plummeted by 40.76% to -$193.4 million in 2023, then surged by 31.76% to -$132.0 million in 2024, then skyrocketed by 146.23% to $61.0 million in 2025.
  • Business Quant data shows Common Equity for CHRS at $61.0 million in Q4 2025, $87.8 million in Q3 2025, and $119.8 million in Q2 2025.